Introduction
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related deaths in women in the United States and the leading cause of gynecologic cancerrelated deaths (Schwartz, 2002; Jemal et al., 2007) . One major limitation in the treatment of EOC is the development of cross-resistance to a wide range of chemotherapeutic agents. Although 80-90% of patients initially respond to first-line chemotherapy such as carboplatin and paclitaxel, less than 10-15% will remain in remission (Jemal et al., 2006) . Treatment advances have led to improved 5-year survival, approaching 45%, but not in overall survival.
Recent studies have demonstrated a potential link between inflammation, cancer progression and chemoresistance (Karin et al., 2002; Balkwill and Coussens, 2004; Chen et al., 2007) . Nuclear factor-kB (NF-kB) is one of the key transcription factors in proinflammatory response, and numerous evidence has been reported that links NF-kB activation and cancer development (Chen et al., 2007) . Cytokines and chemokines, such as interleukin (IL)-6, IL-8, tumor necrosis factor (TNF-a), macrophage chemotactic protein 1 (MCP-1), growthregulated protein a (GRO-a) and migration inhibitory factor (MIF) produced at the microenvironment by immune cells through NF-kB activation, are thought to drive the neoplastic process (Karin et al., 2002) . However, the contribution of cancer cells themselves (especially non-leukemic cancer cells) in the maintenance of a proinflammatory environment that promotes cancer growth is largely overlooked and is sometimes considered passive, even though numerous studies have shown that NF-kB, and its activator IkB kinases (IKKs) are constitutively active in most cancer cells Chen et al., 2007) .
The IKK complex is the direct upstream activator of NF-kB. The canonical IKK complex consists of three major subunits, IKKa, IKKb and IKKg. By phosphorylating the inhibitor of NF-kB a (IkBa), activated IKKs promote the proteosome-mediated degradation of IkBa and nuclear translocation of NF-kB. Although IKKa is more important in cell differentiation, lymphoid organogenesis and the regulation of adaptive immunity (Hacker and Karin, 2006; Liu et al., 2006) , IKKb is crucial for the production of proinflammatory cytokines that are related to cell survival and cell proliferation Hu et al., 2004) . IKKb has been found highly active in many different types of cancer including breast cancer, pancreatic cancer, thyroidal C-cells carcinoma, melanoma and acute myeloid leukemia (Ludwig et al., 2001; Romieu-Mourez et al., 2001; Tamatani et al., 2001; Yang and Richmond, 2001; Baumgartner et al., 2002; Li et al., 2004) . IKKb deletion in mouse enterocytes decreased the incidence of colitisassociated tumor by 75% . In addition, Hu et al. (2004) previously reported that the breast cancer cell line 453 stably expressing IKKb has a higher proliferation rate than its IKKb-negative counterpart.
Furthermore, tumor growth could be considered as a form of abnormal compensatory proliferation in response to injury and tissue damage. This tissue repair process has been reported to depend on Toll-like receptor 4 (TLR4)-MyD88 signaling (Fukata et al., 2005) . TLR4-MyD88 signaling is important to maintain intestinal epithelial homeostasis in response to gut injury, and both TLR4-and MyD88-knockout mice displayed impaired compensatory proliferation and increased apoptosis (Rakoff-Nahoum et al., 2004; Fukata et al., 2005; Pull et al., 2005) . Similarly, in a mouse model of acute lung injury, hyaluronan released from injured cells protected epithelial cells from apoptosis through the TLR2/4-MyD88-NF-kB pathway (Jiang et al., 2005) . Moreover, Medzhitov and colleagues found that spontaneous intestinal tumorigenesis was significantly decreased in MyD88-knockout mice (Rakoff-Nahoum and Medzhitov, 2007) . These animal studies strongly suggest that MyD88 expression and associated molecules may play an important role in tumor progression; however, until now this information has not been confirmed in human cases.
Recently, we described the ubiquitous expression of TLR4 in EOC cells and showed that ligation of TLR4 by lipopolysaccharide (LPS)-or paclitaxel-induced cell proliferation and enhanced cytokine/chemokine production (Kelly et al., 2006) . However, this effect was limited to a group of EOC cells expressing the TLR adaptor protein MyD88 (Kelly et al., 2006) . Constitutive production of cytokines and growth factors are mechanisms that can suppress cancer cell apoptosis and therefore inhibit the efficacy of chemotherapy. Therefore, understanding the intracellular pathways mediating this unique tumor-enhancing characteristic is critical for developing adequate therapies for recurrent and chemoresistant cancer cells.
In this study, we identified IKKb and miR-199a as crucial molecules expressed by EOC cells, which promotes a proinflammatory environment. Using EOC cells isolated from malignant ovarian cancer ascites and solid tumors, we identified IKKb as a major factor promoting a functional TLR-MyD88-NF-kB pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/protumor cytokines and therefore promoting tumor progression and chemoresistance. Our findings demonstrate two possible differential stages in tumor development with unique characteristics in cytokine production, NF-kB regulation and chemoresponse.
Results
Type I EOC cells constitutively secrete protumor cytokines Previously, we identified the differential expression of MyD88 in EOC cells, which correlated with their in vitro response to LPS and paclitaxel (Kelly et al., 2006) . Furthermore, we showed that ligation of TLR4 by LPS or paclitaxel in MyD88-positive (Type I EOC cells) but not MyD88-negative cells (Type II EOC cells) enhanced cytokine/chemokine production (Kelly et al., 2006) . As the tumor microenvironment is determined, in great part, by the factors produced by the tumor cells, our first objective was to characterize the cytokine profile for each of these two cell types. Type I EOC cells (MyD88-positive) are characterized by constitutive secretion of proinflammatory cytokines and chemokines including IL-6, IL-8, MCP-1, MIP-1a, Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES), GRO-a, granulocyte monocyte-colony-stimulating factor (GM-CSF) and MIF (Figure 1) . Conversely, none of these cytokines, with the exception of MIF, were detected in Type II EOC cells (Figure 1 ).
Differential patterns of NF-kB activity in EOC cells
It is well accepted that NF-kB has a central role in the inflammatory response by inducing the production of proinflammatory cytokines (Karin et al., 2002) . Therefore, our next objective was to determine the expression and function of the transcription factor NF-kB and its possible relationship with the continuous cytokine production we observed in Type I EOC cells. We monitored the level of NF-kB activity in both Type I and II EOC cells using a luciferase reporter system (Leung et al., 2006) . As shown in Figure 2a IKKb, ovarian cancer and inflammation R Chen et al differences in NF-kB activity were observed when EOC cells were stimulated with either LPS or paclitaxel (both of which activate NF-kB in a MyD88-dependent pathway). LPS and paclitaxel enhanced NF-kB activity in Type I but not Type II EOC cells, confirming that MyD88 expression is necessary for the effects of these two compounds (Figure 2b ). These data suggest that constitutive NF-kB activity in Type I EOC cells may be responsible for the constitutive production of proinflammatory cytokines, and the induced NF-kB activation may account for the enhanced cytokine production after LPS or paclitaxel stimulation. Indeed, treatment of Type I EOC cells with a specific NF-kB inhibitor, Eriocalyxin B (Leung et al., 2006) , suppressed the production and secretion of cytokines in Type I EOC cells. As show in Figure 2c , the secretion of two NF-kBdependent cytokines, represented by IL-6 and MCP-1, are significantly inhibited following Eriocalyxin B treatment (Figure 2c ). Similar effects were observed for GRO-a, GM-CSF and RANTES (data not shown).
Differential expression and regulation of the inhibitor of NF-kB a (IkBa) in EOC cells We hypothesized that the constitutive NF-kB cyclic activity observed in Type I EOC cells may be the result of specific regulatory elements upstream of the pathway.
Thus, we examined the expression of IkBa, a major inhibitor of NF-kB. Type I EOC cells have low levels of IkBa, whereas high levels of expression was observed in Type II EOC cells (Figure 3a) . Interestingly, this pattern of expression was inversely correlated with MyD88 expression (Figure 3a) . Furthermore, evaluation of IkBa levels over a period of 12 h showed a similar cyclic pattern as observed for NF-kB in Type I but not Type II EOC cells (data not shown). These data demonstrate a correlation between the levels of IkBa and NF-kB activity, suggesting that the differential regulation of NF-kB activity in Type I and II EOC cells may be due to upstream regulators of IkBa.
The degradation of IkBa depends on the phosphorylation of the IKK (Rothwarf and Karin, 1999; Greten and Karin, 2004) . The IKK complex has two catalytic subunits IKKa and IKKb, and an essential regulatory subunit IKKg/NEMO . Differential expression of IKK subunits has been associated with differential cytokine production . Therefore, we hypothesized that the difference we observed in Type I and II EOC cells may be related to the expression of IKK subunits. Thus, the levels of IKKa and IKKb were determined by western blot analysis. We found that the ratio of IKKb/IKKa was significantly higher in Type I than Type II cells (Figure 3b ), suggesting that this differential expression Ectopic expression of IKKb induce cytokine production in Type II EOC cells Deletion of the IKKb subunit has been shown to inhibit inflammatory response Li and Verma, 2002) . As Type II EOC cells express low levels of IKKb, we hypothesized that the ectopic expression of IKKb in these cells will increase the ratio of IKKb/IKKa and may induce Type II EOC cells to produce proinflammatory cytokines. Indeed, the ectopic overexpression of a constitutively active form of IKKb (pCMV2-IKK2 S177E S181E) in Type II EOC cells resulted in a significant decrease in the expression of IkBa (Figure 4a ). The changes in IkBa levels inversely correlated with the IKKb expression levels ( Figure 4a ). Furthermore, IKKb overexpression in Type II cells led to the production of high levels of proinflammatory cytokines similar to that we saw in Type I cells ( Figure 4b ). Interestingly, we also observed increased MyD88 expression in these transfectants (Figure 4a ), which may be the result of NF-kB activation, as MyD88 is also a target of NF-kB (Harroch et al., 1995) .
IKKb overexpression restores TLR4 response in Type II EOC cells
We then evaluated whether the expression of IKKb in Type II EOC cells could mimic the TLR4 response observed in Type I cells. Thus, Type II A2780 cells stably transfected with MyD88 (A2780MyD88 þ ) were transiently transfected with a plasmid expressing the wild-type IKKb gene. After 24 h of transfection, cells were treated with LPS, and cytokine production was determined in both supernatant and cell lysate. As shown in Figure 4c , only cells transfected with IKKb have increased levels of cytokine secretion following LPS treatment. Similar results were seen in cell lysate samples (data not shown). These results confirm the important role of IKKb in cytokine production following TLR4 ligation.
Differential response to tumor necrosis factor-a Tumor necrosis factor-a is a proinflammatory cytokine with divergent effects on cancer cells; in some cases TNF-a induce tumor cell death (Aggarwal, 2003) and in other cases TNF-a may act as tumor promoter through activation of NF-kB (Aggarwal, 2003; Barnhart and Peter, 2003; Chen et al., 2007) . activity by TNF-a has been shown to be dependent on the expression of IKKb and the absence of IKKb is associated with increased susceptibility to TNF-ainduce apoptosis . As Type I and II EOC cells have a differential expression of IKKb, we evaluated the effect of TNF-a on these two cell types. Although Type I cells were resistant to high-dose TNFa-induced cell death (Figure 4d ), Type II cells showed a significant decrease in cell viability and underwent apoptosis as shown by increasing activity of caspases 8, 9 and 3 (Figures 4d and e) , which are the main mediators of TNF-a-induced apoptosis.
Subsequently, we evaluated whether low-dose TNF-a could activate the NF-kB pathway in Type I EOC cells by determining IKKa/b phosphorylation levels. As shown in Figure 4f , treatment with TNF-a (10 ng/ml) induced a time-dependent increase in p-IKKb in Type I cells but not in Type II EOC cells. No changes were observed on p-IKKa in either type of cells (Figure 4f ).
hsa-miR-199a regulates IKKb expression in EOC cells
Evaluation of IKKb mRNA showed similar levels in both cell types (Figure 5a ), suggestive of a posttranscriptional regulation. As microRNAs (miRNAs) are noncoding forms of RNAs involved in posttranscriptional gene regulation, we hypothesized that the differential expression of IKKb protein may be due to miRNA regulation. To examine the potential involvement of miRNAs in the regulation of EOC cell Figure 1) . Eighteen miRNAs were identified to be significantly differentially expressed between the two cell types (Figure 5b ). Three miRNAs are highly expressed in Type II, whereas 15 are downregulated, compared to Type I. Using PicTar (http://www.pictar.bio.nyu.edu/), an algorithm for the identification of microRNA targets, we found that the 3 0 -UTR of IKKb mRNA contains three putative target sequences for hsa-miR-199a, which is one of the three miRNAs upregulated in Type II EOC cells (Figure 5c ). To validate the results from the miRNA microarray, we performed NCode SYBR 
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GreenER miRNA qRT-PCR analysis for hsa-miR199a. Using total RNA from six samples in a blind manner, high levels of hsa-miR-199a expression was detected only in Type II EOC cells (Figure 5d ). To conclusively confirm the role of hsa-miR-199a in the regulation of IKKb, we performed loss or gain of function studies. Transient transfection of the premiRNA of hsa-miR-199a into Type I cells led to a significant decrease in IKKb expression, whereas transient transfection of the anti-miRNA of hsamiR199a into Type II cells resulted in the expression of IKKb (Figure 6a ). We further proved that the (Figure 6b ). Using a construct that highly expresses luciferase, we added the IKKb 3 0 -UTR after the luciferase gene (pmir-RIKK2-3u-1). Afterwards, the construct was transfected into Type I EOC cells (endogenous low levels of hsa-miR-199a), and divided in three groups. Group 1 was transfected with hsa-miR-199a; group 2 received a nonspecific negative control miRNA (miR-NC-no. 1) and group 3 received mock transfection control (only transfection reagent). hsa-miR-199a transfection resulted in significant suppression of luciferase activity compared to mock transfection, whereas negative control miRNA (miR-NC-no. 1) led to no change in the luciferase activity (Figure 6b) . Mutation of the hsa-miR-199a-binding sites in the IKKb 3 0 -UTR completely abolished the inhibitory effect of hsa-miR-199a on luciferase activity (data not shown). These results further confirm a direct inhibition of hsa-miR-199a on IKKb mRNA translation through its 3 0 -UTR.
Discussion
We describe for the first time the differential expression of IKKb in EOC cells isolated from patients with ovarian cancer. We demonstrate that the expression of IKKb in these cancer cells is associated with unique characteristics related to NF-kB activation, TNF-a response, cytokine production and miRNA profiles that correlate to chemoresponse. We further identified hsa-miR-199a as a regulator of IKKb expression. There is compelling evidence that inflammation promotes cancer progression and NF-kB provides the link between these two processes. In fact, recent data directly implicate NF-kB activation as the key component in inflammation-based cancer progression (Pikarsky et al., 2004) . The present results indicate that, in addition to the immune cells, tumor cells may also actively contribute to the inflammatory process that will enhance the repair process and promote cell growth. However, this capacity is not intrinsic to all the cancer cells, but to a selected population that has acquired a functional TLR4-MyD88-NF-kB signaling pathway (Figure 7) .
Interestingly, we found that in addition to MyD88, as we previously reported, high levels of IKKb are also responsible for the phenotype of Type I EOC cells. IKKb is one of the catalytic subunits of the IKK complex that has been shown to be crucial for the NFkB-mediated production of proinflammatory cytokines that are related to cell survival and cell proliferation Hu et al., 2004) , and has been found highly active in many types of cancer (Ludwig et al., 2001; Romieu-Mourez et al., 2001; Tamatani et al., 2001; Yang and Richmond, 2001; Baumgartner et al., 2002; Li et al., 2004) . Consistent with these findings, we observed a correlation between IKKb expression levels, NK-kB activity and cytokine production. All these cytokines and chemokines produced by Type I EOC cells had been shown to be related to cell proliferation and chemoresistance (Coussens and Werb, 2002; Duan et al., 2002; Balkwill, 2004; Nakanishi and Toi, 2005) .
Moreover, the expression of IKKb has been associated with the differential response to TNF-a (Pikarsky et al., 2004) . Although in some cells, TNF-a is able to induce apoptosis in a caspse-dependent manner; in other cells TNF-a induces NF-kB activation through IKKb . Type I EOC cells which express high levels of IKKb are resistant to TNF-a-induced apoptosis and are characterized by increase in pIKKb following TNF-a treatment. This is not the case for Type II EOC cells, which lack IKKb and therefore are sensitive to TNF-a-induced apoptosis. In these cells, TNF-a activates the classical caspase-dependent apoptotic pathway, which involves caspases 8, 9 and 3.
As outlined above, the expression of IKKb has been associated with cytokine production and inflammation (Maeda et al., 2003 (Maeda et al., , 2005 , a characteristic that we found in Type I EOC cells. This role of IKKb was confirmed in our studies where transient overexpression of IKKb in Type II cells restored both the cytokine production and MyD88 expression; therefore, confirming that IKKb pmiR-RIKK2-3U-1 IKKb, ovarian cancer and inflammation R Chen et al plays a very important role in the capacity of Type I cells to promote a proinflammatory environment that could lead to enhanced tumor growth, tumor recurrence and possible chemoresistance.
A major question is then, what regulates the differential expression of IKKb in these two types of EOC cells. One of the differentially expressed miRNA was hsa-miR-199a. Indeed, hsa-miR-199a expression was significantly higher in Type II EOC cells compared with that of Type I and its expression was associated with inhibition of IKKb expression. The characteristics of the three putative target sequences for hsa-miR-199a and mRNA levels for IKKb observed in ovarian cancer cells suggest a translation-inhibitory effect of hsa-miR199a rather than induction of RNA degradation.
Our findings demonstrate for the first time a functional role for hsa-miR-199a as direct inhibitor of IKKb expression. The loss of the inhibitory effect of hsa-miR-199a on IKKb expression in Type I cells may represent an evolutionary fine-tuning during the development of chemoresistant cells. miRNAs may provide invaluable targets to treat chemoresistant cancers.
The data presented in this study suggest that distinct characteristics of Type I and II EOC cells may lead to differential responses to stimulatory signals, including those coming from TLRs. Thus, in Type I cells, due to the high IKKb and low hsa-miR-199a expression, TLR and TNF-a stimulation leads to NF-kB activation and cytokine production, which then may enhance the cells' resistance to cytotoxic drugs such as paclitaxel and TNF-a. In contrast, this response is not observed in Type II cells, which have high levels of hsa-miR-199a and therefore have low levels of IKKb (Figure 7 ).
In conclusion, we describe for the first that hsa-miR199a regulates IKKb expression and this differential expression has significant effect on the type of response of the cancer cells to stimuli. Through their IKKb expression, Type I EOC cells have the capacity to promote a protumor environment, which may have implications in tissue repair, chemoresistance and tumor progression. Identification of these markers in patients' tumor samples may facilitate the adequate selection of treatment, and open new venues for the development of effective therapy for chemoresistant ovarian cancers.
Materials and methods

Patients and samples
Malignant ovarian ascites samples were collected from stage III/IV ovarian cancer patients. Tumor samples were collected from surgery under sterile conditions; one aliquot was -miR-199a ; therefore, when stimulated, nuclear factor-kB (NF-kB) activation leads to cytokine production, cell proliferation and induction of antiapoptotic proteins. In Type II cells expression of IKKb is low due to high hsa-miR-199a expression levels, therefore an incomplete TLR4-MyD88-NF-kB pathway cannot respond to ligands, resulting in no cytokine production and chemosensitivity.
processed for cell preparation and a second aliquot snap frozen in liquid nitrogen for additional use. All patients signed consent forms, and the use of patient samples was approved under Yale University's Human Investigations Committee (HIC no. 10425).
Cell lines and culture conditions
A total of 20 primary EOC cells were used in this study in addition to the human EOC cell lines SKOV3, A2780 and CP70 (gifts from Dr TC Hamilton). Primary EOC cells were isolated from malignant ovarian ascites or ovarian tumors and cultured as previously described (Kamsteeg et al., 2003; Flick et al., 2004 
Protein preparation
Protein extraction was done as previously described (Kamsteeg et al., 2003) . Briefly, cell pellets were lysed on ice in 1 Â phosphate-buffered saline with 1% NP40, 0.1% SDS and freshly added 20 ml/ml protease inhibitor cocktail (Sigma Chemical, St Louis, MO, USA) and 2 mM phenylmethylsulfonyl fluoride (Sigma Chemical). Protein concentration was determined by BCA Protein Assay (Pierce Biotechnology, Rockford, IL, USA), and proteins were stored at À40 1C until further use.
SDS-PAGE and western blots
A quantity of 20 mg of each protein sample was denatured in sample buffer and subjected to 12% SDS-polyacrylamide gel electrophoresis (PAGE) as previously described (Kamsteeg et al., 2003) . The following antibodies were used: rabbit antihuman MyD88 (1:1,000), mouse anti-human IkBa (1:1,000), rabbit anti-human IKKa (1:1,000), rabbit anti-human IKKb (1:2,000) and rabbit anti-human b-actin (1:10,000). Specific protein bands were visualized using the enhanced chemiluminescence assay (Pierce Biotechnology).
NF-kB activity
Nuclear factor-kB activity was measured using a luciferase reporter construct, pBII-LUC containing two kB sites before a Fos essential promoter (a gift from Dr S Ghosh, Yale University). Cells were transiently transfected with pBII-LUC using the FuGENE 6 Transfection Reagent (Roche Applied Science, Indianapolis, IN, USA) following the manufacturer's instructions. Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Briefly, 10 mg of each protein sample in a total volume of 20 ml was mixed with 100 ml of the luciferase assay reagent, and luminescence was measured using TD 20/20 Luminometer (Turner Designs, Sunnyvale, CA, USA). Relative activity was calculated on the basis of readings measured from samples after subtracting blank values, and normalized to b-galactosidase activity expressed by a co-transfected control plasmid. Each sample was performed in triplicates.
Cytokine profiling
Cytokine profiling was performed from protein extracts or culture supernatants using the Luminex 200 system (Luminex Co., Austin, TX, USA) according to the manufacturer's instructions. In summary, 50 ml standard or sample was added to the wells of 96-well plates, and 25 ml microparticle mixture was added to each well. The plates were incubated at room temperature on an orbital shaker (500 r.p.m.) for 2 h. The plates were then washed 3 times with Beadlyte Cell Signaling Assay Buffer (Upstate, Charlottesville, VA, USA) and the microparticles were resuspended in 75 ml Assay Buffer. A quantity of 25 ml of biotinylated detection Ab was added to each well, and after 1.5 h of incubation at room temperature (500 r.p.m.), the plates were washed 3 times with Assay Buffer, and the microparticles were resuspended in 75 ml Assay Buffer. Streptavadin-PE/Assay buffer mixture (1:20) was prepare and 25ml were added per well. After 0.5 h of incubation at room temperature (500 r.p.m.), the plates were washed 3 times with Assay Buffer and resuspended in 125 ml Assay Buffer. The plates were then read by the Luminex 200 Multiplex Analyzer. The final readings were normalized against total cell number of each sample and each sample was performed in triplicates.
IKKb transfection
The plasmid construct overexpressing a constitutively active form of IKKb (pCMV-IKK2 S177E S181E) was obtained from Dr A Rao through www.addgene.com (Plasmid no. 11105). Transient transfection of Type II cells with pCMV-IKK2 S177E S181E, or the empty vector pCMV was carried out using the FuGENE 6 Transfection Reagent (Roche Applied Science) following the manufacturer's instructions. miRNA microarray Analysis with miRNA microarrays each containing 316 analytes were carried out using the NCode Multi-Species miRNA Microarray Kit (Invitrogen) according to the manufacturer's protocol. In summary, miRNA were isolated from total RNA and Poly(A)-tailed followed by ligation of a specific capture sequence through an Oligo(dT) bridge. The tagged miRNA were purified and hybridized to the microarray slides overnight. The slides were then washed and hybridized with Alexa Fluor3/Alexa Fluor5 Capture Reagents. The microarray slides were scanned and quantitated using a GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA). miRNA qRT-PCR Quantitative reverse transcription (qRT)-PCR was performed to detect the levels of hsa-miR-199a in three Type I and three Type II EOC cell lines by NCode SYBRGreenER miRNA qRT-PCR Analysis (Invitrogen) according to the manufacturer's protocol as summarized below. A qRT-PCR forward primer for hsa-miR-199a (5 0 -CCCAGTGTTCAGAC-TACCTGTTC-3 0 ) was designed and synthesized by Invitrogen. A polyadenylation reaction was performed on 500 ng of each total RNA sample using the NCode miRNA FirstStrand cDNA Synthesis Kit (Invitrogen). Quadruplicate qPCR reactions for each cDNA were performed for hsa-miR-199a as well as for the housekeeping control genes b-2-microglobulin (B2 M, RefSeq NM_004048.2, forward primer 5 0 -CCGTGGCCTTAGCTGTGCTC, reverse primer 5 0 -TCCATTCTCTGCTGGATGACG) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, RefSeq NM_002046.3, forward primer 5 0 -CGCTGAGTACGTCGTGGAGTC, reverse primer 5 0 -GCAGGAGGCATTGCTGATGA) using the NCode SYBR GreenER miRNA qRT-PCR Kit (Invitrogen) and a 7900HT qPCR machine (Applied Biosystems, Foster City, CA, USA). The data are shown as fold change compared to sample A2780 after normalization to either housekeeping gene.
RNA isolation and reverse transcription-PCR
Statistical analysis
Data were presented as mean ± s.d. (O'Dwyer et al., 1994) . Statistical significance (Po0.05) was determined using oneway ANOVA with the Bonferonni correction.
